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Abstract
Vitamin K was discovered in 1929 as a substance essential for blood coagulation and
had been clinically utilized before the precise mechanism of action became aware in
1970s. The function as a cofactor of γ-glutamyl carboxylase (GGCX) was the mechanism
firstly discovered with the identification of several substrate proteins including blood
coagulation factors and osteocalcin. Recently, we and others have shown that vitamin
K has other modes of function, such as ligand of nuclear receptor SXR (steroid and
xenobiotic receptor) and its murine ortholog PXR (pregnane X receptor) and modulator
of  protein  kinase  A  (PKA)  activity.  Besides  its  importance  in  blood  coagulation,
involvement  of  vitamin  K  has  been  shown  in  two  major  aging-related  diseases,
osteoporosis and osteoarthritis. Based on clinical and epidemiological studies, vitamin
K is shown to have protective roles for both of them. Interestingly, clinical studies
concerning single  nucleotide  polymorphisms (SNPs)  of  GGCX and γ-carboxylated
status of osteocalcin suggested relationship between GGCX activity and bone-protective
effect, while recent findings from basic research indicated that vitamin K functions
mediated by SXR/PXR as well as GGCX are important in the bone metabolism. We also
suggested that cartilage-protective effect is mediated by SXR/PXR signaling by animal
experiments using Pxr knockout mice.
Keywords: γ-glutamyl carboxylase (GGCX), steroid and xenobiotic receptor (SXR),
pregnane X receptor (PXR), protein kinase A (PKA), osteocalcin, osteoporosis, osteo-
arthritis
1. Introduction
In 1929, a Danish biochemist, Dr. Henrik Dam predicted a fat-soluble diet substance which
is essential for blood coagulation. The substance was referred as “Koagulationsvitamin” in
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German; thus it is called vitamin K in English named after the initial letter of its German
word.  He shared the Nobel  Prize in Physiology or  Medicine in 1943 with an American
biochemist Dr. Edward A. Doisy who later identified the structure of vitamin K. During the
1970s, the mechanism of vitamin K began to be revealed with the discovery, namely, vitamin
K was necessary for γ-carboxylation of some coagulation factors which is catalyzed by an
enzyme called γ-glutamyl carboxylase (GGCX) [1, 2]. Interestingly, warfarin, which inhibits
vitamin K function, was in medical use since 1954, and vitamin K administration to newborn
babies for preventing intracranial hemorrhage started in many countries in the 1960s before
the enzymatic mechanisms of vitamin K function had been clarified.
Recently, epidemiological and clinical studies suggested that vitamin K is related to various
physiological and pathological processes besides coagulation. Based on these studies, vitamin
K was approved to be used as a drug preventing osteoporotic fracture in several Asian
countries. Moreover, for these two decades, another mode of vitamin K action has been
elucidated. We discovered vitamin K functions as a ligand for a nuclear receptor, SXR (steroid
and xenobiotic receptor), and its murine ortholog, PXR (pregnane X receptor) [3], which have
physiological or pathological significance. Summing up, vitamin K plays important roles in
wide variety of biological process in various modes of actions.
In this chapter we are going to introduce novel mechanism of vitamin K action mediated by
SXR/PXR as well as recent findings concerning classical vitamin K action mediated by GGCX.
Then we would like to discuss the functions of vitamin K in some aging-related diseases based
on recent discoveries.
2. Multiple mechanisms of vitamin K function
The classical function of vitamin K is a cofactor of GGCX which was clarified in the 1970s [1,
2]. GGCX catalyzes the addition of a carboxyl group to glutamate residues in the substrate
proteins, which is coupled by oxidization of vitamin K hydroquinone to vitamin K epoxide.
Vitamin K-dependent coagulation factors (II, VII, IX, and X) are well known substrates for
GGCX. They become active when several glutamate residues are γ-carboxylated. So far, 18
human proteins are reported to be γ-carboxylated and their functions are regulated by γ-
carboxylation status in most of them. It is known that cyclic use of vitamin K is necessary for
its function as a cofactor for GGCX [4]. To be recycled, vitamin K epoxide should be reduced
by an enzyme called vitamin K epoxide reductase (VKOR). Warfarin, which has an
anticoagulant activity, inhibits VKOR, causing a subsequent decrease in GGCX activity
(Figure 1).
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Figure 1. Multiple mechanisms of vitamin K actions. (1) GGCX catalyzes conversion of glutamate residues into Gla
residues by incorporating an additional carboxyl group to glutamate. This reaction requires cyclic use of vitamin K.
Vitamin K epoxide reductase (VKOR) is required for recycling vitamin K which is oxidized during γ-glutamyl carbox-
ylation. Warfarin inhibits VKOR and vitamin K recycling, thereby suppressing GGCX activity. Covalent binding of vi-
tamin K epoxide and a target protein is also proposed as a novel mode of vitamin K action which is dependent on
GGCX activity. (2) Vitamin K also functions as a ligand of steroid and xenobiotic receptor (SXR) and its murine homo-
log, pregnane X receptor (PXR). On vitamin K binding, SXR/PXR forms heterodimers with 9-cis-retinoid acid receptor
(RXR), and this complex binds to SXR-responsive elements (SXRE) within the promoter or enhancer regions of target
genes. (3) Vitamin K also activates protein kinase A (PKA) with unknown mechanism. This action was suppressed by
PKA inhibitor but not affected by stimulation with SXR agonist or knocking down of GGCX. Typical substrate of PKA
is CREB (cyclic AMP-responsive element binding protein) and it binds to CRE (cyclic AMP-responsive element) within
the promoter or enhancer regions of target genes when CREB is phosphorylated.
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Recently, another mode of GGCX-dependent vitamin K function was reported in the study of
proapoptotic effect of vitamin K. Handa et al. found proapoptotic protein Bak was covalently
modified by vitamin K epoxide and regulated by its modification [5]. This function is depend-
ent on GGCX-mediated vitamin K function since GGCX activity is required to generate vitamin
K epoxide (Figure 1).
On the other hand, we discovered GGCX-independent mode of vitamin K function mediated
by transcriptional regulation [3] as compared to posttranscriptional modifications explained
above. Vitamin K was found to be one of the ligands of the nuclear receptor, SXR, and its murine
ortholog, PXR. This receptor is also called NR1I2 according to standardized nomenclature
designated by the nuclear receptor committee. In 1998, SXR/PXR was cloned as a novel nuclear
receptor that is mainly expressed in the liver and intestine [6]. At first, its functions were
characterized as a ligand-dependent transcription factor which is activated by various
pharmaceutical agents and xenobiotic compounds [7]. It was originally classified as an orphan
receptor since the endogenous ligand was not known when it was cloned. It was later shown
that some kinds of secondary bile acids (such as lithocholic acid) could be endogenous ligands
for this receptor [8, 9]. It forms a heterodimer with 9-cis-retinoid acid receptor (RXR) on ligand
stimulation. This complex then binds to SXR-responsive elements (SXRE) in the promoter or
enhancer regions of target genes (Figure 1). Some of its target genes are the drug-metabolizing
enzyme, such as CYP3A4, and the ABC (ATP-binding cassette) family transporter, MDR1.
Because of that, a function of SXR/PXR is considered as a xenobiotic sensor-inducing genes
involved in detoxification and drug excretion [10] and named as such. The discovery of novel
vitamin K function as a ligand for SXR/PXR indicated that physiological and pathological
processes mediated by PXR/SXR would be affected by vitamin K.
There is another mode of vitamin K function which modulates activation of signal transduction
pathway. This is inferred by existence of some genes induced by vitamin K, not by SXR agonist,
rifampicin [11]. This induction was not affected by knocking down of GGCX suggesting that
this is γ-carboxylation-independent pathway. Expression of those genes was suppressed by
protein kinase A (PKA) inhibitor, showing the novel vitamin K function as a modulator of PKA
activity (Figure 1).
Inhibition of another protein kinase, protein kinase C (PKC) α and ε, by vitamin K was also
reported [12]. Inhibition of IKK (inhibitor of nuclear factor kappa B kinase) and subsequent
inhibition of NFkB (nuclear factor kappa B) were observed. Whether this function of vitamin
K is independent of mechanisms described above remains to be elucidated.
3. Epidemiological and clinical studies on vitamin K and aging-related
skeletal diseases
A traditional Japanese food, “natto” (fermented soybeans) contains high concentrations of
MK-7, a form of vitamin K2 (menaquinone), synthesized by microorganisms. Epidemiological
study conducted in Japan revealed negative correlation of Natto intake and incidence of hip
fracture [13], which drew attention toward possible link between vitamin K and osteoporosis.
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Later, among several nutrients including vitamin D and calcium, vitamin K was shown to be
the only nutrient that is significantly correlated with hip fracture incidence in Japanese
population [14]. Furthermore, the fracture-preventing effect of vitamin K was observed in
several clinical studies in Japan, which was confirmed by meta-analysis [15]. Based on these
results, vitamin K2 is used for treatment of osteoporosis in several Asian countries. We
previously reported a functional single nucleotide polymorphism (SNP) in GGCX that causes
higher enzymatic activity correlated with higher bone mineral density in elderly Japanese
women [16], suggesting bone-protective function of vitamin K is related to GGCX activity.
Osteocalcin, one of the substrates of GGCX, is specifically expressed in osteoblastic lineage.
The concentration of undercarboxylated form of osteocalcin (ucOC) in serum was reported to
be positively correlated with fracture risk [17]. Measurement of ucOC has been clinically used
to decide the indication of vitamin K for treatment of osteoporosis in Japan. These support the
contribution of GGCX activity to bone-protective effect.
Vitamin K also has some epidemiological evidences in relationship with another skeletal
disease, osteoarthritis. Low vitamin K intake was correlated to the prevalence of osteoarthritis
both in North America and in Japan [18–20]. Unfortunately, therapeutic effect of vitamin K for
established osteoarthritis was not proven by a trial [21], suggesting that the study period was
too short or vitamin K has only preventive effect.
4. Paradoxical GGCX-mediated vitamin K functions on bone metabolism
It is difficult to evaluate vitamin K function on bone tissue mediated by GGCX in vivo due to
its dominant effect on coagulation activity. For example, it is impossible to measure bone
mineral density of adult mice systemically lacking GGCX because Ggcx-knockout mice die
before birth or on the day of birth with massive bleeding [22]. To overcome this obstacle, we
utilized Cre/loxP system which enables tissue-/organ-specific knockout of GGCX dependent
on promoter activity [23] and generated osteoblast-specific GGCX-deficient mice by crossing
with Col1a1-Cre mice [24]. Since osteoblasts express several substrates of GGCX including
osteocalcin, we assumed bone-protective effect of vitamin K is mediated by GGCX activity in
osteoblasts. Surprisingly, the bone mineral density was increased in osteoblast-specific GGCX-
deficient mice and aberrant mineralization was observed in these mice by ultrastructural
analysis. This result indicates that GGCX in osteoblast may not contribute to bone-protective
effect of vitamin K. Moreover, it is contradicting to the clinical studies on GGCX SNPs or ucOC
described above. We speculate that GGCX activity in other tissue is responsible for bone-
protective effect of vitamin K and/or vitamin K function mediated by SXR/PXR that would be
more important in the bone tissue. Further studies are necessary to clarify this enigma. It is
noteworthy that osteocalcin-deficient mice have been shown to have mechanically stronger
bone than wild-type mice [25], suggesting that the decrease of carboxylated osteocalcin, rather
than increase of ucOC, has “bone strengthening effect.”
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5. SXR-mediated vitamin K functions on bone and cartilage
As described above, we proposed another mode of vitamin K function as a ligand of a nuclear
receptor, SXR, and its murine ortholog, PXR. We showed that SXR is also expressed in
osteoblastic cell lines and is activated by vitamin K2 [3]. We further identified SXR-dependent
vitamin K-responsive genes by microarray analysis using human osteoblastic cell line, MG63
cells stably overexpressing SXR [26]. The identified genes included Tsukushi which encodes a
protein that has a collagen-accumulating effect [27], Matrilin2 which encodes a protein
comprising extracellular matrix like collagen [28], and Cd14 which regulates osteoblastogen-
esis [29] and osteoclastogenesis by inducing differentiation of B cells [30, 31]. These genes are
induced even in the presence of warfarin, indicating their induction is independent of GGCX
activity.
The involvement of SXR/PXR signaling in bone metabolism in vivo was suggested by the
bone phenotype of systemic Pxr knockout mice [32]. We showed that 4-month-old female
Pxr knockout mice had lower bone mineral density in femoral bone. Micro-CT analyses
revealed fragile structure in the femoral trabecular bones of Pxr knockout mice. By histo-
morphometrical analyses, enhanced bone resorption and suppressed bone formation were
observed in Pxr knockout mice. The mechanical strength of bone from Pxr knockout mice
was weaker than that of wild-type mice. Negishi et al. reported the phenotype of systemic
Pxr knockout mice from different origins [33, 34]. They also observed lower bone mineral
density in Pxr knockout mice. They proposed a mechanism involving SLC34A2, a trans-
porter of inorganic phosphate, expressed in the intestine. They showed Slc34a2 is a PXR-
responsive gene in the intestine and this was supported by the observation that serum
levels of inorganic phosphate were significantly decreased in Pxr knockout mice. In con-
Figure 2. Aging-dependent wearing of articular cartilage of the knee joint in Pxr knockout mice. Representative micro-
scopic images of articular cartilage of 13-month-old wild-type and Pxr knockout mice are shown. Arrowheads indicate
lateral articular cartilage of the tibia. This difference was not significant in 4-month-old mice, suggesting this is aging-
dependent process. Cited from Azuma et al. [35].
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trast, we did not observe difference in the serum levels of inorganic phosphate between Pxr
knockout mice and wild-type mice [32], suggesting the existence of different mechanisms
according to the mouse strains and/or environment.
We also proposed SXR/PXR-dependent mechanism concerning vitamin K effect on articular
cartilage [35]. We found that systemic Pxr knockout mice displayed aging-dependent wearing
of articular cartilage of knee joints (Figure 2). Remarkable reduction of width and an enlarged
gap between femoral and tibial articular cartilage were observed in Pxr knockout mice in 8-
month-old and 13-month-old mice, but not in 4-month-old mice, indicating this is an aging-
dependent process. With microarray analyses using ATDC5 chondrocytic cells overexpressing
human SXR, we identified Fam20a (family with sequence similarity 20a) as an SXR-dependent
gene induced by SXR ligands. We showed FAM20A related to the higher expression of
COL2A1, a main component of extracellular matrix of the articular cartilages, suggesting the
cartilage-protective effect of FAM20A. These results are consistent with epidemiological
studies showing relationship between vitamin K intake and osteoarthritis and supporting the
potential roles of vitamin K in preventing osteoarthritis caused by aging.
6. Conclusion
In this chapter, we described multiple mechanisms of vitamin K functions clarified so far and
their involvement in aging-related skeletal diseases as examples for their biological signifi-
cance. Besides blood coagulation, osteoporosis, and osteoarthritis, it became gradually aware
that many physiological and pathological phenomena, such as fertility [36], atherosclerosis
[37–39], brain development [40], dementia [41], and glucose metabolism [42–44], are related to
the status of vitamin K sufficiency. We sincerely hope that vitamin K study leads to discoveries
of new biological mechanisms and targets for disease prevention and treatment and eventually
contributes to human culture and welfare.
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